There were 802 press releases posted in the last 24 hours and 200,175 in the last 365 days.

Asia-Pacific COPD Therapeutics Markets 2017-2023 - Bronchodilators and ICS Therapies Dominate the COPD $6.7 Billion Market

/EIN News/ -- Dublin, Feb. 15, 2018 (GLOBE NEWSWIRE) -- The "COPD Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies" report has been added to's offering.

Asia-Pacific (APAC) chronic obstructive pulmonary disease (COPD) market is forecast to grow from around $3.8 billion in 2016 to over $6.5 billion in 2023, at a compound annual growth rate (CAGR) of around 8.7%.

Over the forecast period the prevalence of COPD is expected to increase significantly across the APAC markets, mainly due to an increase in the smoking population, as the disease is more common among smokers (Lim et al., 2015).

Existing COPD therapies are aimed at managing the frequency and severity of the symptoms, and none have been shown to modify long-term disease progression. Roflumilast, which is the only targeted therapy available in the COPD market, has significant anti-inflammatory effects. However, the dosing of roflumilast is limited due to its side effects, which means that the therapeutic benefit is marginal.

The report details the key points driving the COPD market in the five Asia-Pacific markets: India, China, Australia, South Korea and Japan.


  • The COPD Asia-Pacific market will be valued at $6.7 billion in 2023, growing from $3.8 billion in 2016 at a CAGR of 8.7%.
  • Bronchodilators and ICS therapies dominate the COPD market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs?
  • Do branded therapies show continuous growth, and are they facing competition from generics?
  • How will branded therapies be affected by upcoming pipeline therapies?
  • The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.
  • Which molecular targets appear most frequently in the pipeline?
  • Will the pipeline address unmet needs related to limited targeted therapies for COPD patients?
  • What first-in-class triple combinations are due to enter the COPD market within the forecast period, and how will they compete with the currently marketed products?
  • Various drivers and barriers will influence the market over the forecast period.
  • What barriers will limit the uptake of premium-priced therapeutics in the assessed countries?
  • What factors are most likely to drive the market in these countries?

Key Topics Covered:

1 Table of Contents

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.5 Diagnosis
2.6 Disease Stages
2.7 Prognosis
2.8 Treatment Options

3 Marketed Products
3.1 Overview
3.2 Bronchodilator Combination Therapy
3.2.1 Brimica/Duaklir Genuair (aclidinium/formoterol) - AstraZeneca
3.2.2 Spiolto/Stiolto Respimat (tiotropium/olodaterol) - Boehringer Ingelheim
3.2.3 Ultibro (glycopyrronium/indacaterol) - Novartis
3.2.4 Anoro Ellipta (umeclidinium/vilanterol) - GlaxoSmithKline/Theravance
3.2.5 Combivent (ipratropium/albuterol) - Boehringer Ingelheim
3.3 Bronchodilator and Inhaled Corticosteroid Combination Therapy
3.3.1 Symbicort (budesonide/formoterol) - AstraZeneca
3.3.2 Seretide/Advair/Adoair (salmeterol/fluticasone) - GlaxoSmithKline
3.3.3 Relvar/Breo (fluticasone and vilanterol) - GlaxoSmithKline/Theravance
3.4 Bronchodilator Monotherapy
3.4.1 Spiriva (tiotropium) - Boehringer Ingelheim
3.4.2 Foradil (formoterol) - Novartis
3.4.3 Onbrez/Arbeela/Arcapta (indacaterol) - Novartis
3.4.4 Seebri /Tovanor (glycopyrronium) - Novartis
3.4.5 Striverdi Respimat (olodaterol) - Boehringer Ingelheim
3.5 Alternative therapy
3.5.1 Daxas/Daliresp (roflumilast) - Nycomeds
3.5.2 Marketed Products Heatmap

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline Distribution by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline Distribution by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 Mepolizumab - GlaxoSmithKline
4.4.2 Benralizumab - AstraZeneca and MedImmune
4.4.3 PT003 - AstraZeneca/Pearl Therapeutics
4.4.4 PT010 - AstraZeneca/Pearl Therapeutics
4.4.5 Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate -GlaxoSmithKline
4.4.6 CHF-5993 (beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide) - Chiesi Farmaceutici S.p.A.
4.5 Heatmap for Pipeline Products
4.6 Product Competitiveness Framework

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Size
5.2.1 Patient Enrollment per Product by Molecule Type, Molecular Target and Phase
5.2.2 Patient Enrollment per Trial by Molecule Type, Molecular Target and Phase
5.3 Clinical Trial Duration
5.3.1 Clinical Trial Duration by Molecule Type
5.3.2 Clinical Trial Duration by Molecular Target
5.4 Competitive Clinical Trials Metrics Analysis

6 Multi-scenario Forecast
6.1 Geographical Markets
6.2 Asia-Pacific Market
6.3 India
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 China
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 Australia
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 South Korea
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size
6.7 Japan
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Therapy
6.7.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Active Pipeline
7.1.2 Promising Late-Stage Pipeline Products Can Change Treatment Paradigm
7.1.3 Increasing Awareness of COPD
7.1.4 Aging Population
7.2 Barriers
7.2.1 Sales Erosion by Generics
7.2.2 Growing Competition
7.2.3 Low Diagnosis Rates

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals

9 Appendix

Companies Mentioned

  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici S.p.A.
  • GlaxoSmithKline
  • Novartis
  • Nycomeds
  • Pearl Therapeutics
  • Theravance

For more information about this report visit

         Laura Wood, Senior Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Respiratory Drugs

Primary Logo